Bradycardia in a pediatric population after sugammadex administration: case series

Area of Science:

• Anesthesiology
• Pediatric Pharmacology
• Clinical Toxicology

Background:

• Sugammadex is a selective relaxant binding agent used for neuromuscular blockade reversal.
• Approved for pediatric patients over 2 years old, its safety profile in healthy children requires ongoing evaluation.
• While arrhythmias are known, severe bradycardia has not been previously reported in this population.

Observation:

• Two cases of healthy pediatric patients experienced severe bradycardia immediately following sugammadex administration.
• These events occurred despite the absence of pre-existing cardiac conditions or other risk factors.
• The bradycardia was significant enough to warrant medical intervention.

Findings:

• Sugammadex administration was temporally associated with the onset of severe bradycardia in two healthy children.
• This represents a previously unreported severe adverse effect in the healthy pediatric population.
• The mechanism underlying sugammadex-induced bradycardia in children remains to be elucidated.

Implications:

• Clinicians should be aware of the potential for severe bradycardia as an adverse effect of sugammadex in healthy children.
• This finding necessitates careful cardiac monitoring in pediatric patients receiving sugammadex.
• Further research is warranted to understand the incidence, risk factors, and pathophysiology of this adverse event.